BET Bromodomain Inhibition as a Therapeutic Strategy in Ovarian Cancer by Downregulating FoxM1
Open Access
- 1 January 2016
- journal article
- Published by Ivyspring International Publisher in Theranostics
- Vol. 6 (2), 219-230
- https://doi.org/10.7150/thno.13178
Abstract
Ovarian cancer is responsible for the highest mortality among all gynecologic malignancies, and novel therapies are urgently needed to improve patient outcome. Here we performed an integrative genomic analysis and identified the bromodomain and extraterminal domain (BET) protein BRD4 as a potential therapeutic target in ovarian cancer. Suppression of BRD4 using small-molecule BET inhibitors JQ1 and I-BET151, or dual kinase-bromodomain inhibitor volasertib, led to robust and broad antitumor effects across all subclasses of ovarian cancer. In contrast to many other cancers which are susceptible to BET inhibition due to downregulation of super-enhancer-dependent MYC transcript, we discovered that JQ1-sensitive ovarian cancer cells exhibited marked disruption of Forkhead box protein M1 (FoxM1) pathway, a key driver of ovarian carcinoma. These in vitro findings were further supported by in vivo efficacies of JQ1 targeting both cell line-based and patient-derived xenograft models. Our data establish a new treatment strategy against ovarian cancer by employing epigenetic vulnerabilities, and provide a mechanistic rationale for the clinical investigation of BET bromodomain inhibitors in this deadly disease.Keywords
This publication has 41 references indexed in Scilit:
- New Strategies in Ovarian Cancer: Translating the Molecular Complexity of Ovarian Cancer into Treatment AdvancesClinical Cancer Research, 2014
- Better Therapeutic Trials in Ovarian CancerJNCI Journal of the National Cancer Institute, 2014
- New Strategies in the Treatment of Ovarian Cancer: Current Clinical Perspectives and Future PotentialClinical Cancer Research, 2013
- Latest research and treatment of advanced-stage epithelial ovarian cancerNature Reviews Clinical Oncology, 2013
- The Changing View of High-Grade Serous Ovarian CancerCancer Research, 2012
- Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian CancerThe New England Journal of Medicine, 2012
- Integrated genomic analyses of ovarian carcinomaNature, 2011
- ARID1AMutations in Endometriosis-Associated Ovarian CarcinomasThe New England Journal of Medicine, 2010
- The genesis and evolution of high-grade serous ovarian cancerNature Reviews Cancer, 2010
- Frequent Mutations of Chromatin Remodeling Gene ARID1A in Ovarian Clear Cell CarcinomaScience, 2010